Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$0.29 USD
+0.01 (3.21%)
Updated Jul 22, 2024 03:56 PM ET
After-Market: $0.28 -0.01 (-3.11%) 7:28 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LYRA 0.29 +0.01(3.21%)
Will LYRA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LYRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LYRA
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
LYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
Other News for LYRA
Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Lyra to cut 75% of workforce in portfolio shakeup
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
Lyra Therapeutics trading resumes
Lyra implements layoff of 75% of workforce, to evaluate strategic options